Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and MassBio logics (MBL) of the University of Massachusetts Medical School have entered into an agreement to provide Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toroids adsorbed (Ted) vaccine in the US.
Subscribe to our email newsletter
MassBio logic’s Ted vaccine was licensed by FDA in 1970. The vaccine is indicated for active immunization for the prevention of tetanus and diphtheria and is approved for use in people seven years of age and older. Merck is expected to begin distributing MassBio logics Ted vaccine from June 2010.
Sore Christiansen, senior vice president and general manager of adolescent and adult vaccines at Merck Vaccines, said: “Adult vaccination is an important element in Merck commitment to help people be well, and we are delighted to partner with MBL to add tetanus-diphtheria vaccine to our broad US portfolio of adult vaccines.
“This agreement is another example of how Merck engages in partnerships that will enable us to bring the most robust portfolio of products to our customers.”